Effects of cilostazol in patients with Raynaud's syndrome

American Journal of Cardiology

Volumn 92, Issue 11, 2003, Pages 1310-1315

  Rajagopalan, Sanjay ^a,b   Pfenninger, Dana ^a   Somers, Emily ^a   Kehrer, Christine ^a   Chakrabarti, Anjan ^a   Mukherjee, Debabrata ^a   Brook, Robert ^a   Kaplan, Mariana J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Women's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CILOSTAZOL; GLYCERYL TRINITRATE; PLACEBO;

ADULT; ARTERY DIAMETER; ARTICLE; BLOOD VESSEL WALL; BRACHIAL ARTERY; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COLD PRESSOR TEST; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LASER DOPPLER FLOWMETRY; MALE; MICROVASCULATURE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; STANDARD; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY;

EID: 0242488838     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2003.08.013     Document Type: Article

References (30)

1. Regensteiner J.G., Hiatt W.R. Current medical therapies for patients with peripheral arterial disease a critical review . Am J Med. 112:2002;49-57.
2. Reilly M.P., Mohler E.R. III. Cilostazol treatment of intermittent claudication . Ann Pharmacother. 35:2001;48-56.
3. Bennett J.S. Novel platelet inhibitors. Ann Rev Med. 52:2001;161-184.
4. Ikeda U., Ikeda M., Kano S., Kanbe T., Shimada K. Effect of cilostazol, a cAMP phosphodiesterase inhibitor, on nitric oxide production by vascular smooth muscle cells. Eur J Pharmacol. 314:1996;197-202.
5. Nakamura T., Houchi H., Minami A., SakaMoto S., Tsuchiya K., Niwa Y., Minakuchi K., Nakaya Y. Endothelium-dependent relaxation by cilostazol, a phosphodiesterase III inhibitor, on rat thoracic aorta. Life Sci. 69:2001;1709-1715.
6. Elam M.B., Heckman J., Crouse J.R., Hunninghake D.B., Herd K.A., Davidson M., Gordon I.L. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol. 18:1998;1942-1947.
7. Strandness D.E. Jr, Panian S., Rendell M.S., Comp P.C., Zhang P., Forbes W.P. Effect of cilostazol in patients with intermittent claudication a randomized, double-blind, placebo-controlled study . Vasc Endovasc Surg. 36:2002;83-91.
8. Hiatt W.R. Medical treatment of peripheral arterial disease and claudication. N Engl J Med. 344:2001;1608-1621.
9. Dean S.M., Sataiani B. Three cases of digital ischemia successfully treated with cilostazol. Vasc Med. 6:2001;245-248.
10. Maricq H.R., Valter I., Maricq J.G. An objective method to estimate the severity of Raynaud phenomenon digital blood pressure response to cooling . Vasc Med. 3:1998;109-113.
11. LeRoy E.C., Medsger T.A. Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol. 28:2001;1573-1576.
12. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheumatol. 40:1997;1725.
13. Fox R.I. Sjögren's syndrome. Controversies and progress. Clin Lab Med. 17:1997;431-444.
14. Bohan A., Peter J.B. Polymyositis and dermatomyositis (parts 1 and 2). N Engl J Med. 292:1975;344-347. ; 403-407.
15. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., Healey L.A., Kaplan S.R., Liang M.H., Luthra H.S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheumatol. 31:1988;315-324.
16. Alarcon-Segovia D., Cardiel M.A. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol. 16:1989;328-334.
17. Mukerji B., Hardin J. Undifferentiated, overlapping and mixed connective tissue diseases. Am J Med Sci. 305:1993;114-119.
18. Raynaud's Treatment Study Investigators. Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon: results from a randomized clinical trial with 1-year follow-up. Arch Int Med 2000;160:1101-1108.
19. Celermajer D.S., Sorensen K.E., Gooch V.M., Spiegelhalter D.J., Miller O.I., Sullivan I.D., Lloyd J.K., Deanfield J.E. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 340:1992;1111-1115.
20. Brook R.D., Brook J.R., Urch B., Vincent R., Rajagopalan S., Silverman F. Inhalation of fine particulate air pollution and ozone causes acute arterial vasoconstriction in healthy adults. Circulation. 105:2002;1534-1536.
21. Rajagopalan S., Brook R., Mehta R.H., Supiano M., Pitt B. Effect of losartan in aging-related endothelial impairment. Am J Cardiol. 89:2002;562-566.
22. Shamim-Uzzaman Q.A., Pfenninger D., Kehrer C., Chakrabarti A., Kacirotti N., Rubenfire M., Brook R., Rajagopalans S. Altered cutaneous microvascular responses to reactive hyperaemia in coronary artery disease a comparative study with conduit vessel responses . Clin Sci (Lond). 103:2002;267-273.
23. Sagawa A., Watanabe I., Baba Y. Evaluation of the efficacy of pletal for Raynaud's phenomenon of collagen disease. Yakuri to Chiryo. 19:1991;4687-4693.
24. Tsuru T., Tsukamoto H., Hagasawa K. Effect of cilostazol on Raynaud's phenomenon in patients with connective tissue diseases. Igaku to Yakugaku. 30:1993;179-184.
25. Tucker A.T., Pearson R.M., Cooke E.D., Benjamin N. Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynaud's syndrome a randomised trial . Lancet. 354:1999;1670-1675.
26. Lekakis J., Papamichael C., Mavrikakis M., Voutsas A., Stamatelopoulos S. Effect of long-term estrogen therapy on brachial arterial endothelium- dependent vasodilation in women with Raynaud's phenomenon secondary to systemic sclerosis. Am J Cardiol. 82:1998;1555-1557.
27. Meyrick Thomas R.H., Rademaker M., Grimes S.M., MacKay A., Kovacs I.B., Cook E.D., Bowcock S.M., Kirby J.D. Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis. Br J Dermatol. 117:1987;237-241.
28. Watanabe K., Ikeda S., Komatsu J., Inaba S., Suzuki J., Sueda S., Funada J., Kitakaze M., Sekiya M. Effect of cilostazol on vasomotor reactivity in patients with vasospastic angina pectoris. Am J Cardiol. 92:2003;21-25.
29. Nabel E.G., Ganz P., Gordon J.B., Alexander R.W., Selwyn A.P. Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold pressor test. Circulation. 77:1988;43-52.
30. Khan F., Belch J.J. Skin blood flow in patients with systemic sclerosis and Raynaud's phenomenon effects of oral L-arginine supplementation . J Rheumatol. 26:1999;2389-2394.